2023-08-18 14:09:01
© Archyde.com. [0818 종목공시] SK Biopharmaceuticals, epilepsy drug advances into the Middle East…concluded a technology export contract, etc.
Photo = SK Biopharmaceuticals website
[인포스탁데일리=박상철 기자]
■ SK Biopharm (326030) – SK biopharmaceuticals Signed a Strategic Alliance Agreement and a Cenobamate License Agreement for the MENA region of the epilepsy drug cenobamate.
■ Korea Alcohol (017890) – As of the end of 2023, Korea Alcohol plans to pay a cash dividend to enhance shareholder value. (When the subsidiary, Purit Co., Ltd. is listed, 20% of the sales proceeds of the old shares will be differentially distributed to other shareholders excluding the largest shareholder, related parties, and treasury stock as of the end of 2023)
■ KIB Plug Energy (015590) – KIB Plug Energy announced the future business and management plans through the announcement of the hydrogen value chain business. (KIB Plug Energy business structure restructuring)
■ Jiranjigyo Security (208350) – Jiranjigyo Security has decided to sign a trust contract for the acquisition of treasury stock worth KRW 2.00 billion.
■ Unichem (011330) – Uni Co., Ltd. filed a lawsuit for permission to convene a general meeting of shareholders, and the company filed a lawsuit for appointing an prosecutor.
■ Saltlux (304100) – For the purpose of securing operating funds, subsidiary Plutite Co., Ltd. decided to issue 190,838 shares (KRW 4.999 billion) of target class stocks, such as the Korea Investment Re-Up II Fund, through a third-party allocation increase. (Issue price: KRW 26,200)
■ Duckyang Industry (024900) – Signed a supply contract (SW1K new model door trim) worth KRW 508.926 billion (33.00% of recent sales) with Kia Motors. (Contract period: 2025-07-15 ~ 2035-10-15)
Reporter Park Sang-cheol 3fe94@infostock.co.kr
1692377127
#종목공시 #Biopharmaceuticals #epilepsy #drug #advances #Middle #East.. #Signing #technology #export #contract #Infostock #Daily